SURVYR

MDXG

MiMedx Group, Inc.
$3.90
+$0.05 (1.30%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-55%-37%-18%0%+18%Oct 2025Oct 2026Apr 202652w high $7.9752w low $3.03
MDXGSPY
Wall St. Highest PT $8.00 (+105.1%) Wall St. Avg PT $7.40 (+89.7%)
$3$5$7$9$11POC $4Hi $8Avg $7
Underwater Drawdown %Max DD -61.2%Current -51.0%
0.0%-61.2%
Relative Strength vs SPY-55.6% vs SPYUnderperforming
+67%0%-67%
1W
−$0.33 (7.80%)
1M
−$0.77 (16.49%)
3M
−$0.46 (10.55%)
6M
+$0.50 (14.71%)
YTD
−$2.87 (42.39%)
1Y
−$2.83 (42.05%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
5 analysts · mean score 1.20
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$3.90
Average target$7.40
+$3.50 (+89.7%) upsideaverage target vs current price
CurrentAverageMedian
Low$6.00
Median$7.40
High$8.00
12-month Wall Street target range
Recent analyst rating changes · 8
Reiterated
2026-08-27 · Craig-Hallum reiterated Buy on MDXG
Reiterated
2026-08-17 · Cantor Fitzgerald reiterated Overweight on MDXG
Reiterated
2026-04-30 · Citizens reiterated Market Outperform on MDXG
Reiterated
2026-04-20 · Citizens reiterated Market Outperform on MDXG
Reiterated
2026-04-17 · Craig-Hallum reiterated Buy on MDXG
Initiated
2026-02-23 · Citizens started covering MDXG at Market Outperform
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$564.0M
P/E (last 12 months)96.6
P/E (next 12 months, estimated)36.8
52-week range$3.03 – $7.97
Revenue growth (latest quarter vs a year ago)-34.7%
Dividend yieldNo dividend
Analyst consensusStrong Buy (5)
Average analyst price target$7.40 (+90%)

What they do

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for MDXG yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

MDXG earningsReports today
Next report · quarter Sep 2026
Wed Oct 28, 2026After the close
EPS consensus$0.00 range -$0.02–$0.03
Revenue consensus$68.7M 5 analysts
Last 4 quarters · EPS vs estimate
Jul 29, 2026-$0.05est -$0.03−50.0%Below estimates
Apr 29, 2026-$0.05est -$0.04−33.3%Below estimates
Feb 25, 2026$0.14est $0.11+30.2%Above estimates
Oct 29, 2025$0.15est $0.08+100.0%Above estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-21 12:05:40 ET
24-1025-0225-0425-0725-1026-0226-0426-07-0.050.15
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$64.4M-34.7%
2026-03-31$59.0M–
2025-12-31$118.1M–
2025-09-30$113.7M–
2025-06-30$98.6M–

News & catalysts

More news
MiMedx-Sanara Merger Faces Fresh Regulatory Obstacle – SMTI Stock Falls Below This Key Support Level For The First Time In 4 Months
Stocktwits · Oct 16
MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026
GlobeNewswire · Oct 14
MiMedx Says it Received Favorable Court Ruling in Axiofill Classification Matter
MT Newswires · Sep 23
MIMEDX Announces Favorable Federal Court Ruling in AXIOFILL® Regulatory Classification Matter
GlobeNewswire · Sep 23
MIMEDX to Participate in Upcoming Investor Conferences
GlobeNewswire · Sep 08
Rating changes
Reiterated
2026-08-27 · Craig-Hallum reiterated Buy on MDXG
Reiterated
2026-08-17 · Cantor Fitzgerald reiterated Overweight on MDXG
Reiterated
2026-04-30 · Citizens reiterated Market Outperform on MDXG
Reiterated
2026-04-20 · Citizens reiterated Market Outperform on MDXG
Reiterated
2026-04-17 · Craig-Hallum reiterated Buy on MDXG
Initiated
2026-02-23 · Citizens started covering MDXG at Market Outperform

Third-party analyst actions, not SURVYR.'s views. All rating changes

Stats refreshed 2026-10-21 12:05:40 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026